Unicycive Therapeutics, Inc.
UNCY
$6.93
-$0.19-2.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.70% | -45.26% | -35.54% | 58.85% | -20.25% |
| Total Depreciation and Amortization | 33.64% | 47.61% | 59.64% | -46.65% | 50.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.40% | 284.18% | 304.84% | -186.18% | -32.45% |
| Change in Net Operating Assets | -1,294.38% | -117.46% | -291.73% | -342.42% | -359.14% |
| Cash from Operations | -9.60% | -12.72% | -53.09% | -49.01% | -56.29% |
| Capital Expenditure | 66.67% | 8.00% | -161.54% | -355.56% | -500.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -16,698.61% | 8.00% | -161.54% | -355.56% | -500.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,939.24% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -100.00% | -100.00% | 65.62% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 100.00% | 100.00% | -- | -- |
| Other Financing Activities | 64.22% | 60.72% | 75.12% | 90.47% | -69.88% |
| Cash from Financing | 3.06% | -9.64% | -69.21% | -95.72% | 63.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.41% | -42.52% | -184.72% | -218.55% | 77.82% |